1189987-23-2
1189987-23-2
Chemical Structure
Leflunomide-d4
- CAS No.: 1189987-23-2
- Formula:C12H5D4F3N2O2
- Molecular Weight:274.23
IUPAC Name: 5-methyl-N-(4-(trifluoromethyl)phenyl-2,3,5,6-d4)isoxazole-4-carboxamide
InChIKey: VHOGYURTWQBHIL-QFFDRWTDSA-N
SMILES: C(NC1=C(C(=C(C(F)(F)F)C(=C1[2H])[2H])[2H])[2H])(=O)C2=C(C)ON=C2
Biological Activity: Leflunomide-d4 (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Leflunomide-d4 | 99.5% | Leflunomide-d4 (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Leflunomide (Standard) | ≥98% | Leflunomide (Standard) is the analytical standard of Leflunomide. This product is intended for research and analytical applications. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Leflunomide-13C6 | Leflunomide-13C6 (HWA486-13C6) is 13C labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Leflunomide | 99.82% | Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Davis JP, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35(4):1270-3. [Content Brief]
